Chinese patent medicine is one of important parts in Chinese drug market. It is imperative for new drug development and drug policy-making to establish a drug value assessment framework of Chinese patent medicine embodying the characteristics of traditional Chinese medicine. In this study, PubMed, CNKI and other domestic and foreign literature databases as well as the major international government and academic websites were searched to collect literature, policies, standards, guidelines and expert opinions related to drug value assessment at home and abroad. The methods of literature analysis, content analysis and expert consultation were comprehensively adopted to interpret, compare and analyze the relevant laws and regulations. We obtained the core elements and index system of drug value assessment in the world. According to the characteristics of Chinese medicine and the extensive expert consensus, a set of value assessment framework of Chinese patent medicine covering the whole life cycle from the establishment of the R&D project, pre-clinical application, new drug certificate application and post-marketing use is established, providing strong support for the research and development of new Chinese medicine, post marketing re-evaluation, establishment of clinical medication guidelines, drugs pricing, medical insurance compensation and medication choice of patients.
| 科 Family | 属数 Number of genus | 种数 Number of species | 占总种数比例 Percentage of total species (%) | 属 Genus | 种数 Number of species | 占总种数比例 Percentage of total species (%) |
|---|---|---|---|---|---|---|
| 鹅膏菌科Amanitaceae | 2 | 11 | 5.26 | 鹅膏菌属 Amanita | 10 | 4.78 |
| 小菇科 Mycenaceae | 2 | 12 | 5.74 | 丝盖伞属 Inocybe | 5 | 2.39 |
| 多孔菌科 Polyporaceae | 8 | 14 | 6.70 | 蜡蘑属 Laccaria | 5 | 2.39 |
| 红菇科 Russulaceae | 3 | 23 | 11.00 | 小皮伞属 Marasmius | 6 | 2.87 |
| 小菇属 Mycena | 11 | 5.26 | ||||
| 光柄菇属 Pluteus | 5 | 2.39 | ||||
| 红菇属 Russula | 17 | 8.13 | ||||
| 栓菌属 Trametes | 5 | 2.39 |